Filing Analysis
PepGen Inc. reported its Q2 2026 financial results and provided clinical updates regarding its Phase 2 FREEDOM2-DM1 study. The filing includes a recommendation from the DSMB to advance the study into higher dose cohorts.
📋 Key Facts
- Reported Q2 2026 financial results (Item 2.02).
- Updated Corporate Presentation as of August 2026 (Item 7.01).
- DSMB recommended advancing the Phase 2 FREEDOM2-DM1 study into the third and highest multiple ascending dose (MAD) cohort of 12.5 mg/kg.
- DSMB recommended dose escalation in the open-label extension (OLE) study from 5 mg/kg to 10 mg/kg.
PepGen Inc. announced the appointment of Joseph Vittiglio, Esq. as the new Chief Business and Legal Officer on December 8, 2025.
📋 Key Facts
- Appointment of Joseph Vittiglio, Esq. as Chief Business and Legal Officer.
- Effective date of announcement: December 8, 2025.
- The company is an emerging growth company.
PepGen Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025, and provided other business updates via a press release.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes results of operations and financial condition (Item 2.02)
- Press release issued as Exhibit 99.1
PepGen Inc. has approved the repricing of underwater stock options for key executives and employees to encourage retention through March 2025 or a potential sale event. The repricing reduces exercise prices from a range of $8.89–$17.91 down to a flat $4.53 per share.
🚩 Red Flags
- Significant underwater options: Approximately two-thirds of outstanding employee stock options were 'underwater'.
- Executive compensation benefit: Direct financial benefit to the CEO, CFO, and Head of R&D via repricing.
- Potential dilution/incentive misalignment: Repricing can be viewed as a signal that previous equity incentives failed due to stock price decline.
📋 Key Facts
- Effective Date: November 4, 2025.
- Repricing Target: Options with exercise prices above the 52-week high fair market value.
- New Exercise Price: $4.53 per share.
- Original Exercise Price Range: $8.89 to $17.91 per share.
- Total Shares Underlying Eligible Options: 3,557,903 shares.
- Retention Requirement: Participants must remain in service through March 31, 2027, or until a Sale of the Company/Sale Event occurs.
- Scope: Includes CEO James McArthur, CFO Noel Donnelly, and EVP Paul Streck.
PepGen Inc. has updated its Corporate Presentation as of October 1, 2025. This is a routine disclosure under Item 7.01 to provide updated company information to the public.
📋 Key Facts
- Company updated its Corporate Presentation on October 1, 2025.
- The update is furnished as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 liability.
- The filing was signed by Noel Donnelly, Chief Financial Officer.
PepGen Inc. entered into an underwriting agreement to issue 31,250,000 common shares at $3.20 per share, with underwriters exercising their full option for an additional 4,687,500 shares. The offering is expected to net approximately $107.6 million to fund clinical trials and working capital.
🚩 Red Flags
- Significant equity dilution: The issuance of over 35 million new shares represents a substantial increase in the total share count.
📋 Key Facts
- Total Firm Shares: 31,250,000 common stock at $3.20 per share.
- Underwriters exercised the full option for 4,687,500 additional shares on September 25, 2025.
- Estimated net proceeds: $107.6 million (after exercise of option and expenses).
- Use of proceeds: Funding FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, research, development, and working capital.
- The offering was conducted via a shelf registration statement (Form S-3) effective July 8, 2024.
PepGen Inc. issued an 8-K to furnish a press release regarding positive clinical data (highest mean splicing correction in DM1 patients) and an investor presentation regarding the Freedom-DM1 cohort data update.
📋 Key Facts
- Company announced 'Highest Mean Splicing Correction Ever Reported in DM1 Patients' via press release dated September 24, 2025.
- Released a clinical data update presentation titled 'Freedom-DM1, 15 mg/gk Cohort Data Update'.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Data Update Presentation).
PepGen Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings and business updates.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Filing date: August 7, 2025
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
PepGen Inc. reported the results of its 2025 Annual Meeting of Stockholders held on June 4, 2025. The meeting resulted in the election of three Class III directors and the ratification of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2025.
📋 Key Facts
- The 2025 Annual Meeting was held on June 4, 2025.
- A quorum was present with 29,425,676 shares represented out of 32,720,943 total shares entitled to vote.
- Mitchell H. Finer, Ph.D., Heidi Henson, and Laurie B. Keating were elected as Class III directors to serve until the 2028 annual meeting.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
PepGen Inc. is voluntarily discontinuing the development of its PGN-EDO51 program for Duchenne muscular dystrophy (DMD) due to insufficient dystrophin protein increase in clinical cohorts. The company will pivot its focus exclusively to its myotonic dystrophy type 1 (DM1) program.
🚩 Red Flags
- Failure of a primary clinical candidate (PGN-EDO51) to meet meaningful efficacy endpoints for dystrophin increase.
- Significant strategic pivot involving the winding down of an entire R&D program, which may involve resource reallocation and restructuring costs.
📋 Key Facts
- Discontinuation of PGN-EDO51 development for DMD following CONNECT1 study results.
- In the 10 mg/kg cohort (n=4), exon 51 skipped transcripts increased to 4.26%, but total dystrophin only increased to 0.59% of normal levels.
- The company will wind down all DMD-related research and development activities.
- Focus shifts to the DM1 program, specifically the FREEDOM (Phase 1) and FREEDOM2 (Phase 2) clinical trials.
- Data from the FREEDOM-DM1 15 mg/kg cohort is expected in H2 2025; data from the FREEDOM2-DM1 5 mg/kg cohort is expected in Q1 2026.
PepGen Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025, and provided other business updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Filing date: May 8, 2025
- The filing includes an announcement of financial results and general business updates.
- Company is classified as an 'emerging growth company'.
PepGen Inc. announced the appointment of two new directors, Mitchell Finer, Ph.D., and Lisa Wyman, to expand its Board of Directors from six to eight members.
📋 Key Facts
- Board expansion: The number of board members increased from six to eight.
- Dr. Mitchell Finer appointed as Class III director; term expires at 2025 annual meeting or earlier resignation/removal.
- Lisa Wyman appointed as Class I director; term expires at 2026 annual meeting or earlier resignation/removal.
- Compensation for Dr. Finer and Ms. Wyman includes an initial option award of 26,000 shares each (vesting over 3 years) and a $40,000 annual cash retainer.
- Both appointees entered into standard form indemnification agreements.
PepGen Inc. announced the resignation of its Chief Medical Officer, Michelle L. Mellion, MD, effective April 4, 2025. The company stated that her departure is not due to any disagreement with the firm.
🚩 Red Flags
- Loss of key executive (Chief Medical Officer) in a clinical-stage biotech company can impact R&D momentum and regulatory strategy.
📋 Key Facts
- Michelle L. Mellion, MD resigned from her position as Chief Medical Officer on March 24, 2025.
- The resignation becomes effective at the close of business on April 4, 2025.
- The company explicitly stated the resignation is not due to any disagreement with PepGen Inc.
PepGen Inc. filed an 8-K to announce a clinical update regarding its Phase 2 CONNECT2-EDO51 study. The filing serves as a vehicle to incorporate a press release detailing the progress of this specific clinical trial.
📋 Key Facts
- Announcement date: March 4, 2025
- Subject matter: Update on Phase 2 CONNECT2-EDO51 study
- The filing incorporates Exhibit 99.1 (Press Release) by reference.
PepGen Inc. reported its full-year 2024 financial results and announced positive initial clinical data from the FREEDOM-DM1 trial for patients with myotonic dystrophy type 1 (DM1). The company also hosted a conference call to discuss these clinical updates.
🚩 Red Flags
- None identified in this specific filing text.
📋 Key Facts
- Reported Q4 and full-year 2024 financial results on February 24, 2025.
- Announced positive initial results from the ongoing FREEDOM-DM1 trial in patients with DM1.
- Clinical data includes 'robust splicing correction' as reported in Exhibit 99.2.
- The company is an emerging growth company.
PepGen Inc. issued an 8-K to provide clinical program updates regarding its CONNECT study for PGN-EDO51, targeting Duchenne muscular dystrophy (DMD). The filing serves as a vehicle to incorporate a press release containing these scientific/clinical developments.
📋 Key Facts
- The update concerns the CONNECT clinical program investigating PGN-EDO51.
- The drug candidate is intended for patients amenable to an exon-51 skipping approach in Duchenne muscular dystrophy (DMD).
- The announcement was made on January 29, 2025.
PepGen Inc. announced that the FDA has placed a clinical hold on its Investigational New Drug (IND) application for the CONNECT2-EDO51 clinical trial, which targets patients with Duchenne muscular dystrophy (DMD).
🚩 Red Flags
- Clinical hold by FDA represents a significant regulatory setback for the company's lead/key pipeline asset.
- Potential delay in clinical development timelines and increased costs to resolve FDA concerns.
📋 Key Facts
- FDA issued a clinical hold notice regarding the IND application for the CONNECT2-EDO51 trial.
- The target patient population is individuals with Duchenne muscular dystrophy (DMD).
- Announcement date: December 16, 2024.
PepGen Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024, and provided other business updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024
- Filing date: November 7, 2024
- The filing includes the announcement of financial results and general business updates.
PepGen Inc. filed an 8-K to announce its participation in the 29th Annual Congress of the World Muscle Society, where it will deliver presentations.
📋 Key Facts
- The company is presenting at the 29th Annual Congress of the World Muscle Society.
- The announcement was made on October 8, 2024.
- A press release regarding the presentation was issued as Exhibit 99.1.
PepGen Inc. announced the voluntary resignation of Christopher Ashton, Ph.D., from the Board of Directors and its Audit and Compensation Committees, effective September 30, 2024. The company also approved a reduction in board size from seven to six members.
🚩 Red Flags
- Reduction in board size (from 7 to 6) can sometimes indicate shifting corporate governance or strategic changes, though not explicitly stated here.
📋 Key Facts
- Christopher Ashton, Ph.D. resigned from the Board, Audit Committee, and Compensation Committee on September 16, 2024.
- Resignation is effective as of September 30, 2024.
- The resignation was voluntary and not due to any disagreement with the Company's operations, practices, or policies.
- The Board size will decrease from seven directors to six directors following the resignation.
- Habib J. Dable has been appointed to the Audit Committee, effective September 30, 2024.
PepGen Inc. announced the appointment of Paul Streck, M.D., MBA, as the new Executive Vice President, Head of Research & Development on August 20, 2024.
📋 Key Facts
- Appointment of Paul Streck, M.D., MBA as EVP, Head of Research & Development.
- Effective date of appointment: August 20, 2024.
- The announcement was accompanied by a press release (Exhibit 99.1).
PepGen Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided other business updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Filing date: August 8, 2024
- The filing includes results of operations and financial condition as per Item 2.02.
- Press release issued on August 8, 2024, is attached as Exhibit 99.1.
PepGen Inc. announced positive clinical data from the 5 mg/kg dose cohort of its CONNECT1-EDO51 Phase 2 trial for Duchenne muscular dystrophy (DMD). The data showed successful exon skipping and dystrophin production with a favorable safety profile.
📋 Key Facts
- PGN-EDO51 achieved mean exon skipping in biceps tissue of 2.15% at week 13.
- Mean muscle-adjusted dystrophin level was 1.49% of normal (0.70% change from baseline) after 4 doses.
- The 5 mg/kg dose was well tolerated; no discontinuations, dose interruptions, or dose reductions reported.
- Only one mild related treatment-emergent adverse event was recorded.
- No sustained elevation in kidney biomarkers or electrolyte/hepatic function changes observed.
- Two participants have received four doses at the 10 mg/kg level; results expected in early 2025.
PepGen Inc. announced the appointment of two new senior vice presidents to its leadership team on July 2, 2024.
📋 Key Facts
- Afsaneh Mohebbi, Ph.D., has been appointed as SVP - Portfolio and Program Management.
- Dave Borah, CFA, has been appointed as SVP - Investor Relations and Corporate Communications.
- The announcement was made via an 8-K filing on July 2, 2024.
PepGen Inc. held its 2024 Annual Meeting of Stockholders on June 20, 2024, reporting the results of several shareholder votes. Key outcomes included the election of two Class II directors and the approval of an amendment to limit officer liability.
📋 Key Facts
- The 2024 Annual Meeting was held on June 20, 2024.
- Stockholders elected Habib Dable and James McArthur, Ph.D. to the Board of Directors (Class II) to serve until 2027.
- Shareholders approved an 'Officer Exculpation Amendment' to limit the liability of certain officers under Delaware law.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- A quorum was present with 30,365,425 shares represented out of 32,390,445 total shares entitled to vote.
PepGen Inc. announced the promotion of two key executives on June 11, 2024: Michelle Mellion, M.D., to Chief Medical Officer and Hayley Parker, Ph.D., to Senior Vice President, Global Regulatory Affairs.
📋 Key Facts
- Michelle Mellion, M.D., promoted to Chief Medical Officer.
- Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs.
- Announcement date: June 11, 2024.
PepGen Inc. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2024. The filing serves as a formal notice of the release of operational and financial updates.
📋 Key Facts
- Reporting date: May 14, 2024
- Period covered: Quarter ended March 31, 2024
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
PepGen Inc. has adopted its Second Amended and Restated By-laws effective March 15, 2024. The amendments primarily focus on updating corporate governance procedures to align with recent SEC universal proxy rules and Delaware General Corporation Law changes.
📋 Key Facts
- Board of Directors approved the Second Amended and Restated By-laws on March 15, 2024.
- Amendments include revised advance notice by-law provisions.
- Updates made to address SEC Rule 14a-19 (universal proxy rules), specifically regarding proxy solicitation requirements.
- New requirement for stockholders soliciting proxies to use a non-white proxy card color.
- Elimination of the requirement to make stockholder lists available for examination at meetings, per Delaware law updates.
- Clarification of exclusive jurisdiction for legal proceedings in Delaware or U.S. Federal District Courts.
PepGen Inc. announced that it has received U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for its candidate PGN-EDO51 on March 13, 2024.
📋 Key Facts
- Received U.S. FDA Orphan Drug Designation for PGN-EDO51.
- Received U.S. FDA Rare Pediatric Disease Designation for PGN-EDO51.
- Announcement date: March 13, 2024.
PepGen Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023, and provided general business updates via a press release.
📋 Key Facts
- Financial results for the year ended December 31, 2023, were announced on March 6, 2024.
- The filing includes a press release as Exhibit 99.1 containing business updates.
- Company is classified as an emerging growth company.
PepGen Inc. announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has cleared its Clinical Trial Application to proceed with the CONNECT2-EDO51 Phase 2 Clinical Trial.
📋 Key Facts
- Regulatory clearance received from the UK MHRA on March 4, 2024.
- The clearance is for the commencement of the CONNECT2-EDO51 Phase 2 Clinical Trial.
- The announcement was made via an Item 8.01 'Other Events' filing.
PepGen Inc. announced that the U.S. FDA has granted Fast Track Designation for its drug candidate PGN-EDODM1, intended for the treatment of myotonic dystrophy type 1 (DM1). This regulatory milestone is designed to facilitate the development and expedite the review process for this therapeutic candidate.
📋 Key Facts
- FDA granted Fast Track Designation for PGN-EDODM1 on February 20, 2024.
- The target indication is myotonic dystrophy type 1 (DM1).
- Fast Track Designation is intended to facilitate the development and expedite the review of drugs for serious conditions.
PepGen Inc. entered into an underwriting agreement to issue and sell 7,530,000 shares of common stock at $10.635 per share. The offering is expected to net approximately $76.4 million in proceeds to fund clinical development and working capital.
🚩 Red Flags
- Dilution of existing shareholders through a significant new equity issuance
📋 Key Facts
- Aggregate shares to be issued: 7,530,000 shares of common stock
- Offering price: $10.635 per share
- Expected net proceeds: Approximately $76.4 million (after discounts and expenses)
- Underwriter: Leerink Partners LLC
- Use of proceeds: Research/clinical development, working capital, and general corporate purposes
- Cash runway extension: Expected to fund operations into 2026 following the offering
- Expected closing date: February 9, 2024
PepGen Inc. announced the appointment of Mary Beth DeLena as the new General Counsel and Secretary of the Company on January 17, 2024.
📋 Key Facts
- Appointment of Mary Beth DeLena as General Counsel and Secretary.
- Effective date of appointment: January 17, 2024.
- The company is an emerging growth company.
PepGen Inc. announced a clinical milestone regarding the first patient dosed in its CONNECT1-EDO51 Phase 2 Clinical Trial for Duchenne Muscular Dystrophy (PGN-EDO51). This is an operational update related to the company's drug development pipeline.
📋 Key Facts
- First patient has been dosed in the CONNECT1-EDO51 Phase 2 Clinical Trial.
- The trial targets Duchenne Muscular Dystrophy (DMD) patients amenable to Exon 51 skipping.
- Announcement date: January 08, 2024.